The kickoff meeting for the Phase II clinical trial of the Meikokang Biological Recombinant Herpes Zoster Vaccine was successfully held

On May 6th, the kickoff meeting for the Phase II clinical trial of the recombinant herpes zoster vaccine (CHO cells) by Chengdu Maikekang Biotechnology Co., Ltd. (referred to as "Maikekang Biotechnology") was successfully held in Xinxiang, Henan. The next day, the Phase II clinical trial participants will be enrolled.

Phase II Clinical Trial Project Initiation and Researcher Training Meeting

The herpes zoster vaccine developed by Maikokang Biotechnology adopts a recombinant protein technology route and is equipped with a self-developed new MA105 adjuvant system. It is the first complex adjuvant system innovative vaccine in China with independent intellectual property rights and controllable supply chain, and has entered phase II clinical trials. It can promote the body to produce high-level humoral and cellular immunity against varicella zoster virus to prevent herpes zoster. The preliminary safety observation results of the Phase I clinical trial show that this product has good safety and tolerability. The Phase II clinical trial will further expand the enrollment population to evaluate the safety, immunogenicity, and immune persistence of this product and provide data support for the design of the Phase III clinical trial.

Dr. Chen Dexiang, General Manager of Maikokang Biotechnology, stated:

This pipeline has entered clinical phase II, marking another milestone for the company's adjuvant platform to undertake major innovative vaccine development and provide solutions for the prevention and control of major diseases and infectious diseases. Apart from traditional aluminum adjuvants, only six new adjuvants have been approved for marketing globally, but they are all owned by foreign pharmaceutical companies. The Chinese vaccine industry has previously faced the challenge of being choked by new adjuvants. The successful launch of the Phase II clinical trial of the recombinant herpes zoster vaccine based on the MA105 adjuvant system by Maikokang indicates that this vaccine equipped with a new adjuvant system has demonstrated good safety in Phase I clinical trials, and is also a solid step taken by the company in response to the national 14th Five Year Plan's call to address the bottleneck technology of new adjuvants. Through the Phase II clinical trial of this product, we will obtain more immunogenicity and safety data. The company is confident in producing safe and effective vaccines to provide solutions for addressing global public health challenges.

Dr. Chen connected to the site of the Phase II clinical trial project launch and researcher training meeting